NDAINTRAVENOUSSOLUTION
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ROMIDEPSIN (romidepsin) by Teva is (hdac) inhibitor. Approved for cutaneous t-cell lymphoma, peripheral t-cell lymphoma. First approved in 2020.
Drug data last refreshed 20h ago
Mechanism of Action
(HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylated histones,…
Indications (2)
Worked on ROMIDEPSIN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.